In further support of the initial hypothesis that AR activity may drive COVID-19 pathogenesis, a retrospective study during the first months of the pandemic observed a reduced incidence of SARS-CoV-2 infections in prostate cancer patients taking androgen deprivation therapy (ADT) compared to those not receiving ADT (30). This evidence concerns the gene AR and prostate cancer.